Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.

ABSTRACT: Phosphorylated Tau181 (pTau181) in CSF and recently in plasma has been associated with Alzheimer's disease. In the absence of amyloidopathy, individuals with increased total Tau levels and/or temporal lobe atrophy experience no or only mild cognitive decline compared with biomarker-negative controls, leading to the proposal to categorize this constellation as suspected non-Alzheimer's disease pathophysiology (SNAP). We investigated whether the characteristics of SNAP also applied to individuals with increased CSF-pTau181 without amyloidopathy. In this long-term observational study, 285 non-demented individuals, including 76 individuals with subjective cognitive impairment and 209 individuals with mild cognitive impairment, were classified based on their CSF levels of pTau181 (T), total Tau

SUBMITTER: Oberstein TJ 

PROVIDER: S-EPMC9679169 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature